196 related articles for article (PubMed ID: 38483688)
1. Can objective parameters in optical coherence tomography be useful markers in the treatment and follow-up of type 1 and type 2 macular neovascularizations related to neovascular age-related macular degeneration?
Özen O; Koçak Altıntaş AG
Int Ophthalmol; 2024 Mar; 44(1):134. PubMed ID: 38483688
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Optical Coherence Tomography Angiography Parameters in Type 1 Macular Neovascularization Secondary to Age-Related Macular Degeneration.
Arrigo A; Aragona E; Di Nunzio C; Bandello F; Parodi MB
Transl Vis Sci Technol; 2020 Aug; 9(9):48. PubMed ID: 32934898
[TBL] [Abstract][Full Text] [Related]
3. The association of exudation pattern with anatomical and functional outcomes in patients with Neovascular Age-Related Macular Degeneration.
Inan S; Polat O; Karadas M; Inan UU
Rom J Ophthalmol; 2019; 63(3):238-244. PubMed ID: 31687625
[No Abstract] [Full Text] [Related]
4. Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up).
Abdin AD; Hanifa O; Aljundi W; Munteanu C; Seitz B; Suffo S
Graefes Arch Clin Exp Ophthalmol; 2024 Feb; 262(2):457-468. PubMed ID: 37864635
[TBL] [Abstract][Full Text] [Related]
5. Effect of Pro Re Nata Regimen with Anti-VEGF on Type 3 Macular Neovascularization: Long-Term Outcomes.
Toto L; Viggiano P; Quarta A; Grassi M; De Nicola C; Aloia R; D'Aloisio R; Boscia G; Boscia F; Porreca A; Di Nicola M; Savastano MC; Mastropasqua R
Ophthalmic Res; 2024; 67(1):282-291. PubMed ID: 38621369
[TBL] [Abstract][Full Text] [Related]
6. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
Karasu B; Gunay BO
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
[TBL] [Abstract][Full Text] [Related]
7. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
8. [Prognosis criteria of optical coherence tomography angiography for the long-term efficacy of anti-VEGF therapy of neovascular age-related macular degeneration].
Fursova AZ; Nikulich IF; Dmitrieva EI; Gusarevich OG; Derbeneva AS; Vasilyeva MA; Kozhevnikova OS; Kolosova NG; Rabota FK
Vestn Oftalmol; 2023; 139(6):50-58. PubMed ID: 38235630
[TBL] [Abstract][Full Text] [Related]
9. Prospective PED-study of intravitreal aflibercept for refractory vascularized pigment epithelium detachment due to age-related macular degeneration: morphologic characteristics of non-responders in optical coherence tomography.
Clemens CR; Alten F; Termühlen J; Mihailovic N; Rosenberger F; Heiduschka P; Eter N
Graefes Arch Clin Exp Ophthalmol; 2020 Jul; 258(7):1411-1417. PubMed ID: 32306096
[TBL] [Abstract][Full Text] [Related]
10. QUANTITATIVE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY PARAMETER VARIATIONS AFTER TREATMENT OF MACULAR NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION.
Arrigo A; Aragona E; Bordato A; Amato A; Borghesan F; Bandello F; Parodi MB
Retina; 2021 Jul; 41(7):1463-1469. PubMed ID: 33315820
[TBL] [Abstract][Full Text] [Related]
11. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
13. OCT Predictors of 3-Year Visual Outcome for Type 3 Macular Neovascularization.
Sacconi R; Forte P; Tombolini B; Grosso D; Fantaguzzi F; Pina A; Querques L; Bandello F; Querques G
Ophthalmol Retina; 2022 Jul; 6(7):586-594. PubMed ID: 35227948
[TBL] [Abstract][Full Text] [Related]
14. Results of anti-VEGF treatment for neovascular AMD in eyes with different baseline visual acuity in Turkish population-based on real life data-Bosphorus retina study group.
Ozturk M; Ozkaya A; Karabas L; Alagoz C; Alkın Z; Artunay O; Bayramoglu SE; Bolukbasi S; Demir G; Demir M; Demircan A; Erden B; Erdogan G; Erdogan M; Eris E; Kaldirim H; Onur İU; Osmanbasoğlu OA; Erkul SO; Perente İ; Sarici K; Sayin N; Yasa D; Yilmaz İ; Yılmazabdurrahmanoglu Z;
Photodiagnosis Photodyn Ther; 2023 Jun; 42():103640. PubMed ID: 37263398
[TBL] [Abstract][Full Text] [Related]
15. Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography.
Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2089-2096. PubMed ID: 30173338
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and visual outcomes of non-resolving subretinal fluid in neovascular AMD despite continuous monthly anti-VEGF injections: a long-term follow-up.
Hosseini H; Rabina G; Pettenkofer M; Au A; Chehaibou I; Heilweil G; Weiner AJ; Ip M; Loewenstein A; Schwartz SD
Graefes Arch Clin Exp Ophthalmol; 2021 May; 259(5):1153-1160. PubMed ID: 33245430
[TBL] [Abstract][Full Text] [Related]
17. One-year outcomes of anti-vascular endothelial growth factor therapy in peripapillary choroidal neovascularisation.
Singh SR; Fung AT; Fraser-Bell S; Lupidi M; Mohan S; Gabrielle PH; Zur D; Iglicki M; M López-Corell P; Gallego-Pinazo R; Farinha C; Lima LH; Mansour AM; Casella AM; Wu L; Silva R; Uwaydat SH; Govindahari V; Arevalo JF; Chhablani J
Br J Ophthalmol; 2020 May; 104(5):678-683. PubMed ID: 31401554
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Follow-Up of Brolucizumab in Macular Neovascularization.
Ruggeri ML; Toto L; D'Aloisio R; Quarta A; Aloia R; Venturoni P; De Nicola C; Doronzo E; Gironi M; Porreca A; Di Nicola M; Mastropasqua R
Ophthalmic Res; 2023; 66(1):1383-1391. PubMed ID: 38029730
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Drusen and Hyperreflective Foci as Biomarkers for Disease Progression in Age-Related Macular Degeneration Using Artificial Intelligence in Optical Coherence Tomography.
Waldstein SM; Vogl WD; Bogunovic H; Sadeghipour A; Riedl S; Schmidt-Erfurth U
JAMA Ophthalmol; 2020 Jul; 138(7):740-747. PubMed ID: 32379287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
